Altimmune Unveils Pemvidutide Clinical Data at Diabetes Meeting
Altimmune Highlights Pemvidutide at European Diabetes Conference
Altimmune, Inc. (Nasdaq: ALT), a pioneering clinical-stage biopharmaceutical company, has made an exciting announcement regarding its innovative treatment, pemvidutide. The company is set to present groundbreaking data from its Phase 2 clinical study at the prestigious 60th Annual Meeting of the European Association for the Study of Diabetes. This meeting will take place in Madrid, where experts gather to explore advancements in diabetes treatment and research.
Significance of the Clinical Data
The clinical data being showcased focuses on the MRI-based body composition sub-study of pemvidutide in individuals struggling with overweight and obesity. Pemvidutide is a promising investigational drug designed to act as a dual receptor agonist for GLP-1 and glucagon. This treatment aims not only to foster weight loss but also to address metabolic dysfunction associated with steatohepatitis.
Presentation Details
Details of the presentation are as follows:
- Title: Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity: results of a phase 2, MRI-based body composition sub-study.
- Presenter: Sarah Browne, M.D., Vice President of Clinical Development at Altimmune.
- Date/Time: September 10, 2024, at 1:45 pm CEST.
What is Pemvidutide?
Pemvidutide represents a bold step forward in the realm of obesity treatment. By leveraging the synergistic effects of GLP-1 and glucagon, the drug aims to imitate the outcomes of healthy dietary habits and physical exercise. The medicinal properties of GLP-1 help suppress appetite, while glucagon is known for boosting energy expenditure. Beyond aiding in weight loss, glucagon also plays a vital role in enhancing hepatic fat metabolism, leading to favorable outcomes such as decreased liver fat and improved blood lipid profiles.
Clinical Trials and Achievements
To date, clinical trials have illustrated promising results for once-weekly administration of pemvidutide, showcasing significant weight loss along with considerable reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. In recognition of its potential, the U.S. FDA has granted Fast Track designation to pemvidutide, underscoring the urgency of its development for the treatment of MASH. Currently, pemvidutide is completing the MOMENTUM Phase 2 obesity trial and is actively being studied in the ongoing IMPACT Phase 2b MASH trial.
About Altimmune
Altimmune remains committed to developing next-generation peptide-based therapeutics targeting significant health issues. Their efforts toward advancing pemvidutide as a treatment for obesity and MASH exemplify their dedication to innovation in healthcare. For those interested in staying updated on Altimmune's progress and developments, the company offers resources and news through their official website.
Company Contact Information
If you have further inquiries or require additional information, you can reach Altimmune through the following contact details:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
Email: ir@altimmune.com
Frequently Asked Questions
What is the focus of Altimmune's presented data?
The data focuses on pemvidutide's effects on preserving lean body mass during weight loss for individuals with overweight and obesity.
What is pemvidutide?
Pemvidutide is an investigational peptide-based GLP-1/glucagon dual receptor agonist aimed at treating obesity and liver-related metabolic issues.
What are the benefits of GLP-1 and glucagon receptor activation?
Activation of these receptors is thought to imitate the positive effects of diet and exercise, leading to reduced appetite and boosted energy expenditure.
Has pemvidutide received any FDA recognition?
Yes, the U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of metabolic dysfunction-related liver disease.
Who presented the pemvidutide data at the conference?
The data will be presented by Dr. Sarah Browne, Vice President of Clinical Development at Altimmune.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- SS Innovations' First Mantra Surgical System Sale in Latin America
- Yukon Metals Unveils Promising Gold and Copper Discovery
- Constellation Brands Revises Fiscal 2025 Financial Outlook
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Procaps Group Outlines Strategic Vision for Future Success
- GLOBO Language Solutions Explores AI in Medical Interpretation
- Object Management Group Launches New Journal of Innovation
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Optical Modulators Market Growth Metrics and Key Drivers
- ChartPath and WoundZoom Partner to Revolutionize Wound Care
- Affiliated Network Providers and Aurora Health Join Forces
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Johnny Clark Welcomes EFFO: The Ultimate Frying Oil Solution
- Plumas Bank Unveils 2024 Corporate Citizenship Insights
- John Ballantyne Joins Glucotrack Board to Advance Innovation
- Monetary Metals Celebrates SOC 2 Certification Achievement
- Nord Anglia Education Celebrates Student I/GCSE Success
- ThreatHunter.ai Launches Free Cybersecurity Tool for Businesses
- Roper Technologies to Showcase Innovations at GS Conference
- G2 Goldfields Unveils Exciting Drilling Results at OKO
- Celebree School Launches Campaign to Celebrate Literacy Month
- Exploring Stereotaxis Robotic Innovations at HRX Congress
- Kronos Bio to Showcase Research at Key Medical Conferences
- National Police Association Opposes New Liability Insurance Bill
Recent Articles
- Constellation Brands Revises Fiscal 2025 Financial Outlook
- Coloplast A/S Share Trading Insights for Board and Executives
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- LeNae Goolsby's Journey: Reversing Biological Age Naturally
- Rob Faw Unveils Leadership Strategies for Today's Challenges
- Market Insights: Futures Dip Amid Nvidia and Tesla News
- Indonesia Energy Prepares for H.C. Wainwright Conference Focus
- Illumina's Legal Win Against EU Sets New Merger Precedents
- TD Cowen: Trump Win May Postpone Crypto Regulation Changes
- Anavex Life Sciences Teams Up with H.C. Wainwright's Conference
- Revival Gold Revamps Beartrack Earn-In Agreement Terms
- Ecopetrol S.A. Board Resignation and Corporate Decisions Update
- iBio Leaders Set to Speak at Major Investor Conferences
- Protalix BioTherapeutics Eliminates Debt with Note Repayment
- Shoals Technologies Group Wins Favorable ITC Ruling Against Voltage
- Medical Properties Trust Navigates Challenges with New Deal
- Lowe's Companies: A Smart Investment as Elections Approach
- NextEra Energy Announces Investor Meetings for September 2024
- US Dollar Response to ISM Survey and Global Economic Factors
- Kenneth M. Overgaard-Nielsen Joins Computop Management Board
- Global Micellar Water Market Forecast: USD 5.8 Billion by 2033
- 36Kr Holdings Inc. Announces First Half of 2024 Financial Results
- Exploring Roku's Journey: Opportunities Amid Challenges
- NEIRO Commits $100K to Support Shiba Inu Rescue Efforts
- Caliway Initiates CBL-514 Phase 2b Study for Dercum's Disease